Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTITUDE-101: bemarituzumab plus chemotherapy versus placebo plus chemotherapy in first-line FGFR2b-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma
CTR20230994Phase 3Completed
- Sponsor
- Amgen
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of bemarituzumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Amgen. Started Jul 2023; status: completed.
02
Drugs
bemarituzumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20230994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230994.